– Company to Host Conference Call & Webcast at 4:30 p.m. ET –
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) — GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2021, shortly after the NASDAQ market close on Wednesday, August 11. Management will then host a conference call and webcast at 4:30 p.m. ET.
| Title: | GBS,Inc. Fourth Quarter 2021 and Full Year Financial Results Conference Call & Webcast |
||
| Date: | Wednesday, August 11, 2021 | ||
| Time: | 4:30 p.m. ET | ||
| Conference Call Details: |
Toll-Free: 877-407-3982 International: 201-493-6780 Conference ID: 13721414 |
||
| The conference call will be webcast live from the Company’s website and will be available via the following links: | |||
| Webcast: | http://public.viavid.com/index.php?id=145701 https://investors.gbs.inc/news-and-events/investor-calendar |
||
| The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website. | |||
About GBS Inc.
GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes.
For more information, please visit GBS.inc or follow GBS Inc. on Twitter and LinkedIn.
Investor Contact:
LifeSci Advisors, LLC
Jeremy Feffer – Managing Director
212-915-2568
jeremy@lifesciadvisors.com
Company Contact:
The iQ Group Global
Alex Arzeno – VP Investor Relations
alex.arzeno@theiqgroupglobal.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…